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Abstract: The skin-whitening agent, deoxyArbutin, is a potent tyrosinase inhibitor that is 
safer than hydroquinone and arbutin. However, it is thermolabile in aqueous solutions, 
where it decomposes to hydroquinone. Pharmaceutical and cosmetic emulsions are 
normally oil-in-water (o/w) or water-in-oil (w/o) systems; however, emulsions can be 
formulated with no aqueous phase to produce an anhydrous emulsion system. An 
anhydrous emulsion system could offer a stable vehicle for compounds that are sensitive to 
hydrolysis or oxidation. Therefore, to enhance the stability of deoxyArbutin in 
formulations, we chose the polyol-in-silicone, anhydrous emulsion system as the basic 
formulation for investigation. The quantity of deoxyArbutin and the accumulation of 
hydroquinone in both hydrous and anhydrous emulsions at various temperatures were 
analyzed through an established high performance liquid chromatographic (HPLC) method. 
The results indicated that water increased the decomposition of deoxyArbutin in the 
formulations and that the polyol-in-silicone, oil-based, anhydrous emulsion system 
provided a relatively stable surrounding for the deoxyArbutin that delayed its degradation 
at 25 °C and 45 °C. Moreover, the composition of the inner hydrophilic phase, containing 
different amounts of glycerin and propylene glycol, affected the stability of deoxyArbutin. 
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Thus, these results will be beneficial when using deoxyArbutin in cosmetics and medicines 
in the future.  
Keywords:  anhydrous emulsion system; deoxyArbutin; hydroquinone; skin   
whitening; stability 
 
1. Introduction  
Tyrosinase is an enzyme with a copper center that is widely expressed in many life forms and is 
mainly involved in the formation of pigments, such as melanin and other polyphenolic compounds. 
The biosynthesis of melanin in melanocytes might be affected by cellular tyrosinase activity [1,2]. In 
addition, increased production and accumulation of melanin leads to many hyperpigmentation diseases 
such as melasma, solar lentigines, and post-inflammatory hyperpigmentation. Therefore, investigation 
into depigmentation mechanisms and the clinical aspects of skin whitening agents is very   
important [3,4]. Various compounds have demonstrated inhibitory effects on melanogenesis through 
inhibition of the enzymatic activity of tyrosinase [5–7]. For example, hydroquinone (Figure 1A) and 
deoxyArbutin (dA; Figure 1B) are both potent skin-whitening agents that are capable of suppressing 
the function of tyrosinase. DeoxyArbutin (4-[(tetrahydro-2H-pyran-2-yl)oxy]phenol) was first shown 
by Boissy et al. to exhibit greater inhibition of tyrosinase activity and to be safer than hydroquinone 
and arbutin [8]. Moreover, deoxyArbutin demonstrated fast and persistent skin lightening effects both 
in an animal model and in a human trial [9,10]. However, in our previous study, we found that this skin 
whitening agent was thermolabile in aqueous solutions and decomposes to hydroquinone under these 
conditions [11]. Instability in water posed developmental and practical problems for using 
deoxyArbutin in cosmetics and medication. Thus, enhancing the stability of this skin-whitening agent 
is important for its development.  
Figure 1. Chemical structure of hydroquinone (A) and deoxyArbutin (B). 
 
Pharmaceutical and cosmetic emulsions are normally oil-in-water (o/w) or water-in-oil (w/o) systems 
(Figure 2A). However, emulsions can be formulated with no aqueous phase to produce an anhydrous, 
non-aqueous, oil-in-oil or oil-polar solvent emulsion system [12]. A phospholipid-based [13],   
petroleum-formamide/dimethyl formamide/dimethyl sulfoxide-based [14], hydrocarbon-formamide-
based [15] or silicone-based [12] system could offer a stable vehicle for transporting active compounds 
that are sensitive to hydrolysis or oxidation. For instance, a polyol-in-silicone anhydrous emulsion Int. J. Mol. Sci. 2011, 12                 
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system comprised of a polar phase with polyol, which replaces water, and a nonpolar phase with 
silicone oil (Figure 2B) could be used in this manner. Specifically, the polyol in similar systems has 
regularly been selected as propylene glycol, butylene glycol or glycerin.  
Figure 2. Illustration of a normal emulsion (A) and an anhydrous emulsion (B). 
 
To enhance the stability of deoxyArbutin in formulations, we chose the polyol-in-silicone 
anhydrous emulsion system as the basic formulation for investigation. The quantity of deoxyArbutin in 
both a normal (hydrous) emulsion and an anhydrous emulsion at various temperatures were analyzed 
through an established high performance liquid chromatographic (HPLC) method. Moreover, the 
accumulation of hydroquinone in these formulations were analyzed and compared to each other.  
2. Results and Discussion  
The major objective of this work was to examine the stability of deoxyArbutin in an anhydrous 
emulsion system. Therefore, in the first part of the study, we used two polyol-in-silicone anhydrous 
emulsions in formulations containing deoxyArbutin. Secondly, we used an established HPLC method 
to confirm the quantity of deoxyArbutin and hydroquinone in these formulations at various 
temperatures. Thus, the difference in the stability of deoxyArbutin in these normal and anhydrous 
emulsions will be revealed by this study.  
2.1. Preparation of DeoxyArbutin-Containing Formulations 
The compositions of the anhydrous (anH-1/2) and hydrous (H-1/2) formulations used in this study 
are listed in Table 1. We used 4% or 2% cetyl dimethicone copolyol as the emulsifier to formulate the 
silicone-based formulations 1 (anH-1/H-1) and 2 (anH-2/H-2), respectively. The outer phase, or oil 
phase, was produced by adding cyclomethicone with or without stearyl dimethicone and isostearyl 
isostearate. Additionally, the inner phase, or hydrophilic phase, was composed of deoxyArbutin (3%), 
propylene glycol and glycerin, with or without water. In this phase, propylene glycol and glycerin 
provide the solubility of deoxyArbutin. In addition, anhydrous (anH-1/2) and hydrous (H-1/2) 
formulations were defined according to the water content of hydrophilic phase in formulations. Thus, 
we prepared two polyol-in-oil anhydrous emulsions and two water-in-oil (w/o) hydrous emulsions for 
this study (Table 1).  Int. J. Mol. Sci. 2011, 12                 
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Table 1. Compositions of formulations used in this study. 
formulation 
ingredients 
dA cetyl  dimethicone 
copolyol 
cyclomethicone stearyl 
dimethicone 
isostearyl 
isostearate 
propylene 
glycol 
glycerin deionized 
water 
anH-1 3%  4%  17%  0%  0%  46%  30%  0% 
H-1 3%  4%  17%  0%  0%  46%  10%  20% 
anH-2 3%  2%  14%  3%  2%  70%    6%  0% 
H-2 3%  2%  14%  3%  2%  50%    6%  20% 
anH: anhydrous emulsion, H: hydrous emulsion. 
The prepared formulations had no obvious difference in appearance between each other. All 
prepared formulations were centrifuged at 2330× g for 20 min to check the stability of the 
formulations. The results indicated that the formulations made in this study were stable (no phase 
separation occurs) and remained stable until the experiment was completed (14 weeks) and after the 
formulations were incubated at 45 °C (data not shown).  
2.2. Stability of DeoxyArbutin in Formulations at Low Temperature 
To verify the stability of deoxyArbutin in an anhydrous emulsion system, we placed the prepared 
formulations at various temperatures and then analyzed the amount of deoxyArbutin and hydroquinone 
in each formulation on each of the selected days for a total of 98 days (14 weeks). In all of the 
formulations, concentrations of deoxyArbutin were slightly decreased during the time course at 4 °C, 
and the lowest amount of deoxyArbutin, in the H-2 formulation on the 98th day, was 86.08 ± 1.97% 
(Figure 3A). Notably, hydroquinone was not detectable (N.D.) in any of the formulations at any time 
point at 4 °C, except for the H-2 formulation on the 98th day (2.41 ± 0.84%; Figure 3B).  
Figure 3. Stability of deoxyArbutin (A) and the accumulation of hydroquinone (B) at 4 °C 
(low temperature) in various formulations.  
 
Although the difference in the stability of deoxyArbutin in the normal and anhydrous emulsions 
was not evident at 4 °C, there was a slight increase in the stability of deoxyArbutin when the Int. J. Mol. Sci. 2011, 12                 
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formulation was prepared without water (Figure 3A). However, this result also indicated that 
formulated deoxyArbutin kept at a low temperature underwent degradation.  
2.3. Stability of DeoxyArbutin in Formulations at Moderate Temperature 
At 25 °C, the amount of deoxyArbutin in both anhydrous formulations (anH-1/2) was higher than 
that in the hydrous formulations (H-1/2; Figure 4A). On the last day of this experiment, the retention 
percentages of deoxyArbutin in the anH-1 and anH-2 formulations were 76.86 ± 4.11% and   
87.29 ± 4.63%, respectively. Comparatively, the retention percentage of deoxyArbutin in the H-1 and 
H-2 formulations on the 98th day were only 26.49 ± 4.51% and 40.28 ± 3.07%, respectively; thus, we 
concluded that deoxyArbutin in an anhydrous emulsion system was more stable. In addition, the 
accumulation of hydroquinone in these formulations was inversely correlated with the decay of 
deoxyArbutin, such as in formulation H-1, which had the lowest retention percentage of deoxyArbutin 
and the most abundant hydroquinone accumulation (Figure 4A and 4B). This decomposition process in 
aqueous solutions had been demonstrated in our previous study [11].  
Figure 4. Stability of deoxyArbutin (A) and the accumulation of hydroquinone (B) at   
25 °C (moderate temperature) in various formulations.  
 
Moreover, deoxyArbutin was more stable in a water or polyol-in-silicone oil emulsion at 25 °C 
(higher than 84.62% in all formulations on the 21st day) than what was seen in our previous study 
where deoxyArbutin had been dissolved in water with 10% propylene glycol (49.42%) [11]. This 
result indicated that the droplet structures of emulsions provided a stable environment for 
deoxyArbutin and that a similar phenomenon of enhanced drug stability was revealed in numerous 
emulsion systems [16–18].  
2.4. Stability of DeoxyArbutin in Formulations at High Temperature 
At 45 °C and in all formulations, deoxyArbutin decomposed quickly (Figure 5A); however, the 
most unstable surroundings were the water-containing formulations (H-1/2). Moreover, deoxyArbutin 
was completely decayed within two weeks in the H-1 and H-2 formulations at 45 °C, but deoxyArbutin 
in the anH-1 and anH-2 formulations persisted for approximately 40 to 50 days (Figure 5A). These Int. J. Mol. Sci. 2011, 12                 
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results demonstrated that deoxyArbutin in an anhydrous emulsion system was more stable than in a 
hydrous emulsion system. Furthermore, hydroquinone accumulated in all formulations when 
maintained at this temperature (Figure 5B). Although the percentage of hydroquinone was decreased in 
the high temperature environment at the end of this experiment, the relationship between deoxyArbutin 
decomposition and hydroquinone accumulation was still evident (Figure 5A and 5B). In addition, 
hydroquinone at high temperature may also undergo some decomposition process. Thus, the content of 
hydroquinone was decreased after a period of 40–60 days at 45 °C (Figure 5B).  
Figure 5. Stability of deoxyArbutin (A) and the accumulation of hydroquinone (B) at   
45 °C (high temperature) in various formulations.  
 
Furthermore, when comparing formulations 1 and 2, the retention percentage of deoxyArbutin in  
H-2 was higher than in H-1 at 25 °C (Figure 4A), and the retention percentage of deoxyArbutin in 
anH-2 was higher than that in anH-1 at 45 °C (Figure 5A). This consequence possibly resulted from 
the diverse compositions of formulations 1 and 2. For instance, formulation 1 had a higher amount of 
glycerin and a lower amount of propylene glycol (Table 1). This difference provided diverse hydroxyl 
groups in the inner hydrophilic phase of these two types of formulations. Furthermore, the difference 
in the composition of the oil phase could have also presented a minor effect on the stability of 
deoxyArbutin in these formulations (Table 1).  
In summary, water may increase the decomposition of deoxyArbutin in formulations; thus, the 
anhydrous emulsion system could provide a relatively stable surrounding that could delay degradation 
of deoxyArbutin at temperatures of 25 and 45 °C. The results from this study are important for 
improving the formulation for deoxyArbutin. Besides, many factors such as pH value or other 
ingredients in the emulsions also affect the stability of deoxyArbutin. Moreover, the adding of 
stabilizer or antioxidant into the formulation or with oil-in-oil formulations may further enhance the 
stability of deoxyArbutin. In addition, these strategies can also apply to other compounds that are 
sensitive to hydrolysis. We are currently investigating these potential methods to improve the 
applications of deoxyArbutin.  Int. J. Mol. Sci. 2011, 12                 
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3. Experimental Section 
3.1. Materials 
DeoxyArbutin (99.9%) was purchased from Denjelly Co., Ltd (Miaoli, Taiwan, R.O.C), and 
hydroquinone (99.8%) was purchased from Wako Pure Chemical Industries (Osaka, Japan).   
HPLC-grade methanol was purchased from Merck (Darmstadt, Germany), cetyl dimethicone copolyol 
and stearyl dimethicone were purchased from EVONIK Goldschmidt GmbH (Essen, Germany), 
cyclomethicone was purchased from Dow Corning Corporation (Midland, MI, USA), and isostearyl 
isostearate was purchased from Corum Inc. (Taipei, Taiwan, R.O.C). Propylene glycol, glycerin and 
other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), and deionized distilled 
water (ddH2O), which was used for solutions, was obtained with a Milli-Q system (Millipore, Bedford, 
MA, USA).  
3.2. Preparation of Formulations and Emulsion Stability Test 
The compositions of the formulations, including the hydrous and anhydrous emulsions, are listed in 
Table 1. DeoxyArbutin (3%) was first pre-dissolved in propylene glycol, and all formulations were 
prepared by premixing the hydrophilic and hydrophobic phases. After premixing, the hydrophilic and 
hydrophobic components were emulsified via a high-shear mixer at an agitation speed of 200 rpm for  
2 min. Subsequently, increase the agitation speed at 1000 rpm for 5 min to complete the emulsification. 
To test the stability of emulsions, all prepared formulations were centrifuged at 2,330× g for 20 min to 
check their stability. Besides, at every time point, the formulations were also determined whether the 
phase separation occurs to confirm the emulsions are stable.  
3.3. Sample Preparation and High Performance Liquid Chromatography (HPLC) Analysis 
For sample preparation, 0.25 g of emulsion was dissolved in 50 mL of methanol and then sonicated 
for 30 min in a water bath sonicator. The extracted sample was subsequently diluted (1:24 (v/v)) for 
analysis in pure methanol. The analytic procedures for deoxyArbutin and hydroquinone were 
performed according to our previous study [11]. Specifically, each 20-μL sample was injected into the 
HPLC apparatus (Agilent 1100 series, USA), which utilized a pre-packed C18 reversed-phase column 
(Mightysil RP-18, GP 250-4.6, Kanto Chemical, Tokyo, Japan). The mobile phase, composed of 
methanol and water (60:40 (v/v), pH 7), was run at a flow rate of 1 mL/min The solvents were filtered 
separately through a 0.45 mm filter (Millipore) and mixed in the desired proportions. The UV 
wavelength was set to 280 nm for detection of both deoxyArbutin and hydroquinone, and the ratios of 
the compound peak areas to the internal standard peak areas were calculated using the corresponding 
concentrations. These ratios were then used to obtain the calibration graph. In the determination of 
hydroquinone, the percentage of hydroquinone was calculated by the molar ratio of deoxyArbutin to 
hydroquinone, i.e., 3 g of deoxyArbutin can completely decompose to 1.701 g of hydroquinone.  Int. J. Mol. Sci. 2011, 12                 
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3.4. Stability Studies of DeoxyArbutin in the Emulsion System 
The normal and anhydrous formulations containing 3% deoxyArbutin were placed in glass bottles 
and kept in the dark. Once in an incubator, these samples were exposed to the following temperatures: 
4 °C (low temperature), 25 °C (moderate temperature) and 45 °C (high temperature). At each of the 
designated time points, the formulations were analyzed using the previously described HPLC method 
to monitor the stability of deoxyArbutin and hydroquinone in these emulsion systems.  
3.5. Statistical Analysis 
All data were obtained in three independent experiments and then analyzed to determine the mean 
values. Statistical comparisons of the means and simple correlation coefficients were performed using 
the Student’s t-test.  
4. Conclusions  
In conclusion, we have demonstrated that water may enhance the decomposition of deoxyArbutin in 
formulations and that a polyol-in-silicone oil-based anhydrous emulsion system can provide a 
relatively stable surrounding that delays the degradation of deoxyArbutin at temperatures of 25 and  
45 °C. Moreover, the composition of the inner hydrophilic phase, which contains a different amount of 
glycerin and propylene glycol, might affect the stability of deoxyArbutin. Therefore, the results from 
this study can help in determining practical uses for deoxyArbutin in cosmetics and medicines in  
the future.  
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